---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088578"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:16:21.525653+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q2 revenue $37.2M, net loss $45.7M; FY2024 guidance cut to $170-175M

## Summary
- Q2 revenue $37.2M (pro forma combined -23% YoY); net loss $45.7M; adjusted EBITDA loss $31.0M.
- FY2024 revenue guidance reduced to $170-$175M from prior expectation; cites weaker SomaScan services and capital spending slowdown.
- Accelerated merger synergy target: $80M cost reductions expected operationalized by end of 2024, a year ahead of plan.
- Repurchased ~11.3M shares in Q2 for ~$29M at avg $2.57/share; cash position $396M.
- Revenue decline primarily from timing of large customer projects in Europe and constrained capital purchase environment.

## SEC filing metadata
- accession: 0000950170-24-088578
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017024088578/0000950170-24-088578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017024088578/lab-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088578
- JSON: https://secwatch.observer/filing/0000950170-24-088578.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.